Open AccessAn international discrete choice experiment assessing patients' preferences for disease-modifying therapy attributes in multiple sclerosis
Author(s) -
Birgit Bauer,
Bernd Brockmeier,
Virginia Devonshire,
Arthur Charbonne,
Daniela Wach,
Barry Hendin
Publication year - 2020
Publication title -
neurodegenerative disease management
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.674
H-Index - 23
eISSN - 1758-2032
pISSN - 1758-2024
DOI - 10.2217/nmt-2020-0034
Subject(s) - dosing , medicine , regimen , multiple sclerosis , sample (material) , intensive care medicine , family medicine , psychiatry , chemistry , chromatography
Aim: This discrete choice experiment aimed to assess patients' preferences for treatment attributes in multiple sclerosis (MS). Patients & methods: Patients with relapsing-remitting MS completed an online survey assessing treatment preferences. Descriptive statistical analysis and discrete choice hierarchical Bayesian modeling were performed. Results: Across the overall sample (n = 485), dosing regimen, efficacy and safety were equally important. Within the whole sample, and among those diagnosed <10 years ago, intravenous infusion ≤3 times/year was the preferred dosing regimen; among patients diagnosed ≥10 years ago it was preferred equally to oral treatments. Patients were more willing to accept frequent but mild over rare but severe side effects. Conclusion: Several factors influence patient preferences for MS treatments and must be considered in patient-centered care.